EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific

Gizem Mayis Bilgin iD, Syarifah Liza Munira, Kamalini Lokuge, Kathryn Glass

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0294091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Gizem Mayis Bilgin und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australia. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Antiviral Agents, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Decision-makers in middle-income countries need evidence on the cost-effectiveness of COVID-19 booster doses and oral antivirals to appropriately prioritise these healthcare interventions.

Methods

We used a dynamic transmission model to assess the cost-effectiveness of COVID-19 booster doses and oral antivirals in Fiji, Indonesia, Papua New Guinea, and Timor-Leste. We conducted cost-effectiveness analysis from both healthcare and societal perspectives using data collated from publicly available sources. We developed an interactive R Shiny which allows the user to vary key model assumptions, such as the choice of discounting rate, and view how these assumptions affect model results.

Findings

Booster doses were cost saving and therefore cost-effective in all four middle-income settings from both healthcare and societal perspectives using 3% discounting. Providing oral antivirals was cost-effective from a healthcare perspective if procured at a low generic price (US$25) or middle-income reference price (US$250); however, their cost-effectiveness was strongly influenced by rates of wastage or misuse, and the ongoing costs of care for patients hospitalised with COVID-19. The cost or wastage of rapid antigen tests did not appear strongly influential over the cost-effectiveness of oral antivirals in any of the four study settings.

Conclusions

Our results support that COVID-19 booster programs are cost-effective in middle-income settings. Oral antivirals demonstrate the potential to be cost-effective if procured at or below a middle-income reference price of US$250 per schedule. Further research should quantify the rates of wastage or misuse of oral COVID-19 antivirals in middle-income settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisAntiviral AgentsCOVID-19SARS-CoV-2HumansAdministration, OralImmunization, SecondaryIndonesiaCOVID-19 VaccinesFijiCOVID-19 Drug TreatmentPapua New GuineaCost-Effectiveness Analysis

Substanzen

Antiviral AgentsCOVID-19 Vaccines

Autor:innen und Institutionen

  • National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australia.
  • Faculty of Economics and Business, Universitas Indonesia, Jakarta, Indonesia.

ORCID-Profile: Gizem Mayis Bilgin

Zitieren

APA

Bilgin, G. M., Munira, S. L., Lokuge, K., & Glass, K. (2024). Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific. PLOS ONE. https://doi.org/10.1371/journal.pone.0294091

Vancouver

Bilgin GM, Munira SL, Lokuge K, Glass K. Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific. PLOS ONE. 2024. doi:10.1371/journal.pone.0294091

BibTeX
@article{Bilgin2024,
  author = {Bilgin, Gizem Mayis and Munira, Syarifah Liza and Lokuge, Kamalini and Glass, Kathryn},
  title = {Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0294091}
}
Kostenlos starten →